when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

Eli Lilly and Co · news · pharmadog

← back to Eli Lilly and Co

News mentioning Eli Lilly and Co

123 stories

19dNovo looks to Anthropic’s AI models to ‘supercharge’ drug developmentbiopharma dive

22dSTAT+: What’s in a name? Novo looks to a rebrandstat

25dNovartis’ board faces investor scrutiny after M&A misfires and R&D flopsbiospace

26d11 companies hiring in California nowbiospace

26dSandoz plans ‘vast and vertically integrated’ supply chain to support 100-biosimilar visionbiospace

27dSTAT+: Leukemia drug data suggested a different way to treat diabetes. A new biotech will test that ideastat

27dCaspian launches with $50M, Lilly support to advance disease-modifying diabetes betbiospace

27dNovartis’ $12B Avidity acquisition hits Phase 3 speedbump as dystrophy drug disappointsbiospace

27dMoonwalk pulls in $70M to take fat-targeting RNAi obesity candidate to clinicbiospace

28dNovartis’ cholesterol-lowering medicine fails Phase 3, clouding Lp(a) horizonsbiospace

Sep 2, 26Novartis’ and BMS’ paused CAR T trials, RevMed’s pancreatic cancer approval, more MFN dealsbiospace

Aug 31, 26Deal-hungry Lilly strikes up to $2.9B immuno play for Meridabiospace

Aug 28, 26This week in charts: Biotech’s rebound is undeniablebiopharma dive

Aug 28, 26Lilly joins Novo in cardiovascular space after FDA nod for GLP-1/GIP agonist Mounjarobiospace

Aug 27, 26Myriad catalysts on deck for obesity’s brightest stars as market continues to acceleratebiospace

Aug 26, 26Research into protein interactions sheds new light on causes of autismfiercebiotech

Aug 26, 26Zepbound may cut healthcare costs, study says; Summit, Akeso drug hits in another China trialbiopharma dive

Aug 26, 26Capricor’s DMD therapy still alive, Merck/Moderna’s cancer vax shines, FDA’s future revealedbiospace

Aug 25, 26Lilly takes oral obesity race abroad with UK launch of Foundayobiospace

Aug 25, 26Massachusetts biopharma jobs, including R&D positions, fell in 2025: Reportbiospace

Aug 24, 26Roche bets up to $2.3B in Hanmi pact for next-gen weight loss drugbiospace

Aug 21, 26Shareholder pressures Capricor; Lilly dives deeper into vaccinesbiopharma dive

Aug 21, 26How cost and perception could reshape the GLP-1 marketbiopharma dive

Aug 20, 26Roche pours $750M into Oregon manufacturing plant as obesity push expandsbiospace

Aug 19, 26Amylyx’s redemption story, Summit’s survival woes, Definium’s anxiety win, morebiospace

Aug 19, 26Novo takes first round of oral obesity duel. Can it stay ahead of Lilly?biospace

Aug 18, 26Sandoz inks $322M Henlius deal for rights to as many as 10 biosimilarsbiospace

Aug 18, 26Rebounding biotech funds expected to spur CDMO growth within yearbiospace

Aug 18, 26Amylyx’s bet on a GLP-1 blocker pays offbiopharma dive

Aug 17, 26STAT+: Pharmalittle: We’re reading about an AstraZeneca setback, falling U.S. drug prices, and morestat

← prevpage 2 of 5next →